Appili Therapeutics Inc. (OTCMKTS:APLIF) Short Interest Up 2,866.7% in August

Appili Therapeutics Inc. (OTCMKTS:APLIF) was the target of a large growth in short interest in the month of August. As of August 15th, there was short interest totalling 17,800 shares, a growth of 2,866.7% from the July 31st total of 600 shares. Based on an average trading volume of 171,000 shares, the days-to-cover ratio is currently 0.1 days.

Appili Therapeutics Stock Performance

Shares of Appili Therapeutics stock opened at $0.03 on Wednesday. Appili Therapeutics has a 1 year low of $0.02 and a 1 year high of $0.07. The company has a market capitalization of $3.24 million, a P/E ratio of -0.89 and a beta of -0.49. The company’s fifty day moving average is $0.03 and its two-hundred day moving average is $0.03.

Appili Therapeutics (OTCMKTS:APLIF) last released its earnings results on Tuesday, August 13th. The company reported ($0.01) EPS for the quarter, hitting the consensus estimate of ($0.01).

About Appili Therapeutics

Appili Therapeutics Inc, a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of an antibiotic, metronidazole; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701 is a live-attenuated vaccine for Francisella tularensis.